Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
21,283 total articles
Kura Oncology posted $5.8 million in net product revenue from KOMZIFTI in the first full quarter since commercialization, showing strong physician adoption and payer coverage. The company is advancing multiple clinical trials for ziftomenib in AML, with anticipated 2026 data readouts supporting its broad use. The robust cash position and collaborat…
Aura Biosciences, a clinical-stage biotech company specializing in precision therapies for solid tumors, announced that its senior management will participate in two major investor conferences in May 2026 to discuss the company's developments and outlook. Live webcasts will be available and archived on the company's investor relations website.
IZEA Worldwide reported a Q1 2026 revenue of $6.6 million, an 18% decrease year-over-year, reflecting their strategic shift away from low-margin SMB accounts toward higher-value enterprise clients. Despite the revenue decline and a net loss of $0.8 million, the company launched ZED, an AI-powered marketing platform, secured new major clients, and m…
Pacira BioSciences issued a letter to its stockholders ahead of the 2026 Annual Meeting, advocating for votes in favor of its three board nominees. The company emphasizes the nominees' extensive experience in healthcare and biopharmaceutical sectors aligned with Pacira's strategic goals, contrasted against the underqualified nominees proposed by ac…
Inhibikase Therapeutics announced the commencement of its pivotal Phase 3 IMPROVE-PAH clinical trial targeting Pulmonary Arterial Hypertension (PAH) with its lead candidate IKT-001. The company secured regulatory approvals across 16 countries including the US and EU, benefiting from the EMA's FAST-EU initiative to expedite trial sites activation. F…
Verrica Pharmaceuticals reported a 51.3% year-over-year increase in dispensed YCANTH applicator units and $5.0 million revenue in Q1 2026, highlighting growing adoption of their FDA-approved treatment for molluscum. The company advanced its global Phase 3 trial enrollment for YCANTH's new use in common warts and expanded commercial launch into Japa…
OptimizeRx Corp. reported Q1 2026 revenue of $19.8 million, a 10% decrease year-on-year, but achieved a narrowed GAAP net loss of $0.5 million and increased adjusted EBITDA to $3.3 million. The company updated its fiscal year 2026 revenue guidance higher to $95-$100 million while maintaining adjusted EBITDA guidance at $21-$25 million. Subsequent t…
Nkarta, Inc. reported its Q1 2026 financial results and corporate updates, highlighting progress in its NKX019 clinical trials (Ntrust-1 and Ntrust-2) for autoimmune diseases. The company secured FDA agreement for outpatient dosing, protocol amendments including re-dosing and expanded indications, and obtained multiple IRB approvals. Nkarta maintai…
BIO-key International's Nasdaq-listed shares (BKYI) will be suspended as of May 12, 2026, due to the stock price failing to maintain Nasdaq's $1 minimum bid price for the required duration and delays in filing its annual report. The company will temporarily trade on the OTC Markets while seeking to restore its Nasdaq listing. Despite the suspension…
Maze Therapeutics announced positive topline Phase 2 trial data for MZE829 in APOL1-mediated kidney disease (AMKD), demonstrating clinical proof-of-concept and supporting advancement to a pivotal trial. It plans to start Phase 2 trials for MZE782 in phenylketonuria (PKU) and chronic kidney disease (CKD) in 2026, with topline data expected in 2027. …
Cytokinetics announced participation in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference. The company highlighted progress on its cardiac drug candidates, including the approved MYQORZO® (aficamten) for obstructive hypertrophic cardiomyopathy and positive Phase 3 results for aficamten in non-obstructive HCM. They continu…
Molecular Partners reports progress in its lead Radio-DARPin MP0712 with a Phase 1/2a study underway in multiple US clinical sites and initial data expected in 2026. The company unveiled an isotope-agnostic Radio-DARPin strategy enabling flexible therapeutic payloads and strengthened its financial position with CHF 79 million cash, supporting pipel…
South Jersey Industries, Inc. announced a cash tender offer to repurchase all outstanding 2018 Series A 3.70% Remarketable Junior Subordinated Notes due 2031 at $920 per $1,000 principal amount plus accrued interest. The offer aims to refinance debt subject to market and legal conditions, with no minimum tender amount required. The tender will expi…
IDT Corporation’s BOSS Money digital remittance service achieved record remittances sent to Mother’s Day destinations, with a 49% increase in principal and 27% more transactions compared to last year, emphasizing strong growth in their digital remittance business and expanding customer trust.
22nd Century Group, Inc. announced that the FDA has accepted for scientific review the company's renewal applications for their VLN® King and VLN® Menthol King cigarettes, the first combusted cigarettes authorized as Modified Risk Tobacco Products (MRTP). These renewals, if approved, will allow continued marketing of these reduced nicotine cigarett…
Skye Bioscience reported Q1 2026 financial results and provided a business update focusing on the advancement of its nimacimab obesity treatment program. The company initiated enrollment in Cohort 1 of the CBeyond Expansion Study, completed compatibility studies to support subcutaneous delivery, and is on track to report topline data in Q4 2026. Sk…
SEGG Media, a Nasdaq-listed sports and entertainment company, announced its expanded partnership with Soccerex by becoming the official headline sponsor for all 2026 and 2027 Soccerex events. The company is actively participating in Soccerex Europe 2026 in Amsterdam, engaging with key football stakeholders to grow its sports media and fan engagemen…
South Jersey Industries, Inc. has announced a cash tender offer to repurchase any and all of its outstanding 2018 Series A 3.70% Remarketable Junior Subordinated Notes due 2031 at $92 per $1,000 principal amount plus accrued interest. The offer expires on May 26, 2026, with settlement on May 29, 2026. Completion of the tender is contingent upon cer…
Kyivstar Group Ltd., Ukraine's leading digital operator listed on Nasdaq, held its 2026 Annual General Meeting where shareholders re-elected the current board and Chairman Kaan Terzioğlu, demonstrating continued confidence in the company's strategic direction. Kyivstar reported strong 2025 financial results with a 25.9% increase in revenue to USD 1…
Linkhome Holdings Inc. (Nasdaq: LHAI), an AI-driven real estate and fintech platform, has entered into a definitive agreement to acquire Mortgage One Group, a mortgage lending company operating in 18 U.S. states. This acquisition aims to integrate Mortgage One Group's lending infrastructure with Linkhome's AI technology to create an advanced AI-pow…
Octave Intelligence plc, a subsidiary of Hexagon AB, has filed and registered a prospectus for its admission to trading on Nasdaq Stockholm (SDRs) and Nasdaq New York (Class B ordinary shares). The distribution of Octave shares to Hexagon shareholders is scheduled with key trading dates in May 2026, marking Octave's debut as a publicly-traded compa…
Tevogen Bio Holdings Inc. announced a private investment in public equity (PIPE) financing of $3 million at $8 per prefunded warrant, representing a 14% premium over the previous closing price. The financing, backed by existing investor The Patel Family, LLP, aims to support ongoing operations, strategic growth, and general corporate purposes. The …
Avista Utilities has commenced operations of the first community-based microgrid in the region at the Dr. Martin Luther King Jr. Family Outreach Center in Spokane. The microgrid integrates solar power, battery storage, and natural gas to maintain reliable power during outages, allowing the center to remain operational and reduce energy costs. This …
Syndax Pharmaceuticals highlighted 12 abstracts featuring their FDA-approved menin inhibitor Revuforj (revumenib) accepted for presentation at the European Hematology Association (EHA) 2026 Congress. The data demonstrate strong activity across various subtypes of acute leukemia, favorable tolerability, promising post-transplant maintenance outcomes…
Plains All American Pipeline and Plains GP Holdings finalized the sale of Plains Midstream Canada, their natural gas liquids (NGL) business, to Keyera Corp for net proceeds of approximately $3.3 billion. The transaction supports debt reduction and strategic focus on crude oil midstream operations with more stable cash flows and reduced volatility. …
